|
Toll Free: (877) 796-6397 -- USA and Canada only -- |
Fax: +1-832-582-8590 Orders: +1-832-582-8158 |
Tech Support: +1-832-582-8158 Ext:3 Please provide your Order Number in the email. |
Technical Data
| Formula | C21H22F2N6O2
|
|||
| Molecular Weight | 428.44 | CAS No. | 1223403-58-4 | |
| Solubility (25°C)* | In vitro | DMSO | 86 mg/mL (200.72 mM) | |
| Ethanol | 86 mg/mL (200.72 mM) | |||
| Water | Insoluble | |||
|
* <1 mg/ml means slightly soluble or insoluble. * Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations. * Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.) |
||||
Preparing Stock Solutions
Biological Activity
| Description | Larotrectinib (Vitrakvi, LOXO-101, ARRY-470) is an ATP-competitive, oral administered and highly selective inhibitor of the tropomyosin-related kinase (TRK) family receptors. | |
|---|---|---|
| Targets |
|
Protocol (from reference)
Selleck's Larotrectinib has been cited by 18 publications
| Establishment and large-scale validation of a three-dimensional tumor model on an array chip for anticancer drug evaluation [ Front Pharmacol, 2022, 13:1032975] | PubMed: 36313330 |
| Larotrectinib induces autophagic cell death through AMPK/mTOR signalling in colon cancer [ J Cell Mol Med, 2022, 26(21):5539-5550] | PubMed: 36251949 |
| Influence of Tyrosine Kinase Inhibition on OATP1B3-mediated Uptake [ Mol Pharmacol, 2022, MOLPHARM-AR-2021-000287] | PubMed: 35383108 |
| Patient-derived tumor organoids for personalized medicine in a patient with rare hepatocellular carcinoma with neuroendocrine differentiation: a case report [ Commun Med (Lond), 2022, 2:80] | PubMed: 35789568 |
| Entrectinib Induces Apoptosis and Inhibits the Epithelial-Mesenchymal Transition in Gastric Cancer with NTRK Overexpression [ Int J Mol Sci, 2021, 23(1)395] | PubMed: 35008821 |
| TRK inhibitors block NFKB and induce NRF2 in TRK fusion-positive colon cancer [ Journal of Cancer, 2021, 12(21): 6356-6362] | PubMed: None |
| Mechanisms of targeted therapy resistance in a pediatric glioma driven by ETV6-NTRK3 fusion [ Cold Spring Harb Mol Case Stud, 2021, 7(5)a006109] | PubMed: 34429303 |
| An Organoid Biobank of Neuroendocrine Neoplasms Enables Genotype-Phenotype Mapping [ Cell, 2020, 183(5):1420-1435.e21] | PubMed: 33159857 |
| TRK Fusions Are Enriched in Cancers with Uncommon Histologies and the Absence of Canonical Driver Mutations [ Clin Cancer Res, 2020, 26(7):1624-1632] | PubMed: 31871300 |
| Identification of Novel Fusion Genes in Bone and Soft Tissue Sarcoma and Their Implication in the Generation of a Mouse Model [ Cancers (Basel), 2020, 12(9)E2345] | PubMed: 32825119 |
RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.
SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.
NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.